NEW YORK – The National Institute for Health and Care Excellence (NICE) in the UK on Thursday published a final draft guidance recommending that the National Health Service make available gilteritinib (Astellas' Xospata) monotherapy for patients with FLT3-mutated acute myeloid leukemia.